A2CPS Genetic Variant Core
A2CPS Genetic Variant Core
批准号:
9812621
负责人:
KELLY A FRAZER
金额:
$2.22万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-01 至 2023-07-31
关键词:
AcuteAcute PainAdherenceBiological MarkersBlood specimenClinicalClinical DataCollaborationsCollectionCommunicationComplexDNADataData AnalysesData Coordinating CenterData SetDepositionDetectionDevelopmentEnsureGenerationsGeneticGenomic medicineGoalsHuman ResourcesIndividualInstitutesKnowledgeLongitudinal cohortMetadataMethodsMolecularMultiomic DataMusculoskeletalOperative Surgical ProceduresPainParticipantPatientsPersonsPhenotypePredispositionPrevention strategyProceduresProcessProtocols documentationQuality ControlReportingReproducibilityResearch DesignResearch PersonnelResistanceResourcesSamplingTraumaValidationVariantWorkanalysis pipelinebiomarker selectioncandidate markercandidate selectionchronic paindata integrationdata submissionexperiencegenetic associationgenetic predictorsgenetic selectiongenetic signaturegenetic variantimaging biomarkermeetingsnovelpersonalized strategiesprimary outcomeprogramspsychosocialrecruitresiliencesample collectionscreeningsexskills
中文摘要
遗传变异核心
总结
慢性疼痛是一个复杂的问题,可能受到多种环境和遗传因素的影响。增长
慢性疼痛的遗传基础的证据表明,可能使用遗传预测因子,
区分患者可能对慢性疼痛的发展敏感与有弹性。这
该项目是组学数据生成中心(ODGC)的基因变异核心(GVC),用于急性至慢性
疼痛特征(A2 CPS)程序。在本计划中,临床中心将招募和收集临床数据,
生物流体样品来自两个纵向队列,每个队列1800名受试者。将在第0、3和
急性疼痛发作后6个月,包括特定外科手术或特定肌肉骨骼
外伤这些样本将用于生成多组学数据,以验证40种主要结局生物标志物
表明对慢性疼痛发展的易感性或恢复力,以及鉴定新的候选者
生物标志物。对于拟议的基因变异核心,将在第1年执行的目标1将涉及关闭
与A2 CPS计划的其他组成部分合作,以建立最终的研究设计和方案。所有
A2 CPS项目的研究人员将共同努力,建立40个主要结果生物标志物。的
ODGC和临床中心研究者将共同决定具体的样本类型,
收集/处理/存储方法。ODGC和数据集成资源中心/数据协调
组成部分(DIRC/DCC)调查人员将建立元数据和数据标准以及工作流程,
向DCC提交元数据和数据。GVC和ODGC的行政核心将建立
用于样品和数据跟踪以及元数据记录的集成LIMS。GVC和DIRC/数据
集成和分析组件(DIAC)将建立数据分析管道。目标2和目标3将跨越
2-4,目标2侧重于3600名参与者样本的DNA分离和遗传变异阵列,
由临床中心收集。目标3将包括向DIRC/DCC提交元数据和数据,
数据的质量控制以及数据分析和解释。此组件的主要目标是生成
并提交高质量的基因变异阵列数据,用于验证预选遗传变异
生物标志物。虽然这项研究并不能确定新的遗传关联,但我们希望能扩大研究范围。
分析联合选择的遗传变异生物标志物以外的其他变异,
对慢性疼痛的敏感性/恢复力。GVC成分调查人员将参与综合分析,
DIRC/DIAC旨在开发由多种生物标志物类型(包括分子,
临床、心理社会和/或成像生物标志物),其指示对慢性疼痛的易感性/恢复力,
用于制定预防和治疗慢性疼痛的个性化策略。这方面的人员
建议的GVC已经获得了必要的技能和知识,成功地执行这个项目,
参与多个大型项目,生成遗传变异阵列数据。
英文摘要
GENETIC VARIANT CORE
SUMMARY
Chronic pain is a complex problem, likely influenced by multiple environmental and genetic factors. Growing
evidence for a genetic basis for developing chronic pain suggests it may be possible to use genetic predictors to
differentiate between patients likely to be susceptible versus resilient to the development of chronic pain. This
project is the Genetic Variant Core (GVC) of the Omics Data Generation Center (ODGC) for the Acute to Chronic
Pain Signatures (A2CPS) Program. In this Program, the Clinical Centers will recruit and collect clinical data and
biofluid samples from two longitudinal cohorts of 1800 subjects each. Biofluid samples will be collected 0, 3, and
6 months after an acute pain episode, consisting of a specific surgical procedure or a specific musculoskeletal
trauma. These samples will be used to generate multi-omic data to validate 40 primary outcome biomarkers
indicating susceptibility or resilience to development of chronic pain, as well as to identify new candidate
biomarkers. For the proposed Genetic Variant Core, Aim 1, which will be executed in Year 1, will involve close
collaboration with other components of the A2CPS Program to establish the final study design and protocols. All
of the A2CPS Program investigators will work together to establish the 40 primary outcome biomarkers. The
ODGC and Clinical Center investigators will jointly decide on the specific sample type(s) and
collection/processing/storage methods. The ODGC and Data integration Resource Center/Data Coordination
Component (DIRC/DCC) investigators will establish Metadata and Data Standards and a workflow for
submission of metadata and data to the DCC. The GVC and the Administrative Core of the ODGC will establish
an integrated LIMS for sample and data tracking, and recording of metadata. The GVC and DIRC/Data
Integration and Analysis Component (DIAC) will establish data analysis pipelines. Aims 2 and 3 will span Years
2-4, with Aim 2 focused on DNA isolation and genetic variant arrays for the 3600 participant samples that will be
collected by the Clinical Centers. Aim 3 will encompass submission of metadata and data to the DIRC/DCC,
quality control of the data, and data analysis and interpretation. The primary goal of this Component is generation
and submission of high-quality gene variant array data for the validation of pre-selected genetic variant
biomarkers. While the study is not powered to identify novel genetic associations, we expect to extend the
analysis beyond the jointly selected genetic variant biomarkers to include additional variants implicated in
susceptibility/resilience to chronic pain. GVC component investigators will participate in integrative analyses with
the DIRC/DIAC aimed at developing pain signatures comprised of multiple biomarker types (including molecular,
clinical, psychosocial, and/or imaging biomarkers) indicating susceptibility/resilience to chronic pain, which can
be used to develop personalized strategies for prevention and treatment of chronic pain. The personnel for this
proposed GVC have acquired the necessary skills and knowledge to successfully execute this project from
participation in multiple large-scale projects generating genetic variant array data.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetic & Social Determinants of Health: Center for Admixture Science and Technology
-
批准号:10818088
-
项目类别:
-
资助金额:$192.87万
-
财政年份:2023
-
负责人:KELLY A FRAZER
-
依托单位:
Genetic & Social Determinants of Health: Center for Admixture Science and Technology
-
批准号:10307040
-
项目类别:
-
资助金额:$251.08万
-
财政年份:2021
-
负责人:KELLY A FRAZER
-
依托单位:
Genetic & Social Determinants of Health: Center for Admixture Science and Technology
-
批准号:10492767
-
项目类别:
-
资助金额:$260.8万
-
财政年份:2021
-
负责人:KELLY A FRAZER
-
依托单位:
Genetic & Social Determinants of Health: Center for Admixture Science and Technology
-
批准号:10599760
-
项目类别:
-
资助金额:$21.18万
-
财政年份:2021
-
负责人:KELLY A FRAZER
-
依托单位:
Omics Data Generation Center (ODGC) for the Acute to Chronic Pain Signatures (A2CPS) Program
-
批准号:10199703
-
项目类别:
-
资助金额:$12.81万
-
财政年份:2019
-
负责人:KELLY A FRAZER
-
依托单位:
A2CPS Genetic Variant Core
-
批准号:10224834
-
项目类别:
-
资助金额:$20.99万
-
财政年份:2019
-
负责人:KELLY A FRAZER
-
依托单位:
A2CPS Genetic Variant Core
-
批准号:10000902
-
项目类别:
-
资助金额:$20.93万
-
财政年份:2019
-
负责人:KELLY A FRAZER
-
依托单位:
A2CPS Genetic Variant Core
-
批准号:10457871
-
项目类别:
-
资助金额:$9.62万
-
财政年份:2019
-
负责人:KELLY A FRAZER
-
依托单位:
Omics Data Generation Center (ODGC) for the Acute to Chronic Pain Signatures (A2CPS) Program
-
批准号:9812619
-
项目类别:
-
资助金额:$6.65万
-
财政年份:2019
-
负责人:KELLY A FRAZER
-
依托单位:
Optimizing HaploSeq for whole-genome phased haplotypes in biomedical applications
-
批准号:8833411
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2015
-
负责人:KELLY A FRAZER
-
依托单位:
Optimizing HaploSeq for whole-genome phased haplotypes in biomedical applications
-
批准号:9268995
-
项目类别:
-
资助金额:$3.01万
-
财政年份:2015
-
负责人:KELLY A FRAZER
-
依托单位:
Functional Analysis of T2D Associated Non-coding SNPs
-
批准号:8894331
-
项目类别:
-
资助金额:$90.7万
-
财政年份:2015
-
负责人:KELLY A FRAZER
-
依托单位:
Biomarkers of Disease Progression in CLL
-
批准号:7976892
-
项目类别:
-
资助金额:$26.88万
-
财政年份:2010
-
负责人:KELLY A FRAZER
-
依托单位:
Biomarkers of Disease Progression in CLL
-
批准号:8094505
-
项目类别:
-
资助金额:$9.78万
-
财政年份:2010
-
负责人:KELLY A FRAZER
-
依托单位:
Large-Scale Low-Cost Genotyping for the Haplotype Map
-
批准号:6917488
-
项目类别:
-
资助金额:$608.36万
-
财政年份:2004
-
负责人:KELLY A FRAZER
-
依托单位:
Genetic Association in Austism Disorder
-
批准号:6834394
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2004
-
负责人:KELLY A FRAZER
-
依托单位:
Evolutionary Conserved Sequences in the Human Genome
-
批准号:6549176
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2002
-
负责人:KELLY A FRAZER
-
依托单位:
Evolutionary Conserved Sequences in the Human Genome
-
批准号:6805136
-
项目类别:
-
资助金额:$47.32万
-
财政年份:2002
-
负责人:KELLY A FRAZER
-
依托单位:
Evolutionary Conserved Sequences in the Human Genome
-
批准号:7053757
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2002
-
负责人:KELLY A FRAZER
-
依托单位:
Evolutionary Conserved Sequences in the Human Genome
-
批准号:6796118
-
项目类别:
-
资助金额:$46.96万
-
财政年份:2002
-
负责人:KELLY A FRAZER
-
依托单位:
海外基金